The relationship between total dose, number of fractions and fraction size in the response of malignant melanoma in patients

1978 ◽  
Vol 51 (611) ◽  
pp. 905-909 ◽  
Author(s):  
Shirley Hornsey
Keyword(s):  
Malignant Melanoma ◽  
Total Dose ◽  
Fraction Size ◽  
Dose Number ◽  
The Relationship

scholarly journals Chondroitin polymerizing factor (CHPF) promotes development of malignant melanoma through regulation of CDK1

2020 ◽  
Vol 11 (7) ◽  
Author(s):  
Wei Sun ◽  
Fang Zhao ◽  
Yu Xu ◽  
Kai Huang ◽  
Xianling Guo ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Pathway Analysis ◽  
Normal Skin ◽  
Over Expression ◽  
Tumor Promotor ◽  
And Migration ◽  
First Time ◽  
The Relationship

Abstract Chondroitin polymerizing factor (CHPF) is an important member of glycosyltransferases involved in the biosynthesis of chondroitin sulfate (CS). However, the relationship between CHPF and malignant melanoma (MM) is still unknown. In this study, it was demonstrated that CHPF was up-regulated in MM tissues compared with the adjacent normal skin tissues and its high expression was correlated with more advanced T stage. Further investigations indicated that the over-expression/knockdown of CHPF could promote/inhibit proliferation, colony formation and migration of MM cells, while inhibiting/promoting cell apoptosis. Moreover, knockdown of CHPF could also suppress tumorigenicity of MM cells in vivo. RNA-sequencing followed by Ingenuity pathway analysis (IPA) was performed for exploring downstream of CHPF and identified CDK1 as the potential target. Furthermore, our study revealed that knockdown of CDK1 could inhibit development of MM in vitro, and alleviate the CHPF over-expression induced promotion of MM. In conclusion, our study showed, as the first time, CHPF as a tumor promotor for MM, whose function was carried out probably through the regulation of CDK1.

The relationship of psychosocial factors to prognostic indicators in cutaneous malignant melanoma

1985 ◽  
Vol 29 (2) ◽  
pp. 139-153 ◽  
Author(s):  
Lydia Temoshok ◽  
Bruce W. Heller ◽  
Richard W. Sagebiel ◽  
Mardsen S. Blois ◽  
David M. Sweet ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Psychosocial Factors ◽  
Cutaneous Malignant Melanoma ◽  
Prognostic Indicators ◽  
Relationship Of ◽  
The Relationship

Predictive and prognostic effect of ABO blood group on immune checkpoint inhibitors

2021 ◽  
pp. 1-8
Author(s):  
Yakup Ergun ◽  
Selin Akturk Esen ◽  
Murat Bardakci ◽  
Gokhan Ucar ◽  
Ziya Kalkan ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Blood Group ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Blood Groups ◽  
Abo Blood Group ◽  
Blood Group System ◽  
Advanced Malignant Melanoma ◽  
The Relationship

BACKGROUND: The relationship of the ABO blood group system with the immune response is known, but its relationship with immune checkpoint inhibitors (ICIs) has not been clearly investigated until now. OBJECTIVE: In this study, the relationship between different blood groups and nivolumab treatment response in patients with advanced malignant melanoma was investigated. METHODS: The data of patients who used nivolumab for advanced malignant melanoma between April 2018 and April 2021 were retrospectively reviewed. RESULTS: A total of 73 patients were included in the study. In the progression-free survival (PFS) analysis according to blood groups, it was 3.9 months, 16.1 months, 20.0 months and 3.0 months for A, B, AB and O, respectively (p= 0.1). Overall survival (OS) analysis according to blood groups was 5.1 months, 25.0 months, 20.0 months and 9.3 months for A, B, AB and O, respectively (p= 0.1). The B antigen group (B or AB) had significantly longer PFS and OS than the non-B antigen group (A or O) (16.1 vs. 3.5 months for PFS, respectively, p= 0.03; 20.0 vs. 7.4 months for OS, respectively, p= 0.02). CONCLUSIONS: The presence of B antigen provides a significant advantage in terms of survival in patients using ICIs for advanced melanoma.

scholarly journals Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression

1993 ◽  
Vol 68 (4) ◽  
pp. 746-750 ◽  
Author(s):  
PG Natali ◽  
MR Nicotra ◽  
MF Di Renzo ◽  
M Prat ◽  
A Bigotti ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Tumour Progression ◽  
The Relationship

The relationship between fractional lymphocyte counts and survival in malignant melanoma.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e20116-e20116
Author(s):  
Michael Thomas McCarthy ◽  
David James Gallagher
Keyword(s):  
Malignant Melanoma ◽  
The Relationship

scholarly journals The relationship between mitotic rate and depth of invasion in biopsies of malignant melanoma

2018 ◽  
Vol Volume 11 ◽  
pp. 125-130 ◽  
Author(s):  
Hamid Reza Ghasemi Basir ◽  
Pedram Alirezaei ◽  
Sara Ahovan ◽  
Abbas Moradi
Keyword(s):  
Malignant Melanoma ◽  
Mitotic Rate ◽  
Depth Of Invasion ◽  
The Relationship
Sign in / Sign up

Export Citation Format

Share Document